Compare Amylx Pharmaceuticals Inc (AMLX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while Consumer Discretionary Select Sector SPDR Fund trades at $118.11. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | XLY | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | — |
52-Week High | $24.19 | $124.52 |
52-Week Low | $7.82 | $105.64 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
XLY trades at $118.02, down 1.38% today, with a bullish technical signal from moving averages but overbought RSI readings. Analyst consensus is unanimously positive, with a 100% buy rating. The ETF focuses on consumer discretionary stocks, benefiting from economic trends favoring the sector.
Outlook remains favorable due to strong analyst support and sector momentum, though overbought conditions and consumer spending sensitivity pose near-term risks. Long-term growth hinges on sustained economic strength and discretionary demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
